Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor typesCombinations of PD-1 + TIGIT inhibitors have potential to expand... | January 10, 2022

Related Keywords

China ,Guangzhou ,Guangdong ,Shanghai ,United States ,Suzhou ,Jiangsu ,Beijing ,Maryland ,Canada ,San Francisco ,California ,America ,Chinese ,Denny Lanfear ,Sheng Yao ,Eli Lilly ,Mcdavid Stilwell ,Junshi Biosciences ,Theresa Lavallee ,Coherus Biosciences ,Zhi Li ,Kelli Perkins ,Institute Of Microbiology Chinese Academy ,Ir Team ,Coherus Biosciences Inc ,Shanghai Junshi Biosciences Co Ltd ,National Reimbursement Drug List ,National Medical Products Administration ,Pr Team ,Junshi Bioscience ,Chinese Mainland ,For Global ,Southeast Asia ,Senior Vice President ,Chief Development Officer ,New Drug Applications ,Prescription Drug User Fee Act ,Breakthrough Therapy ,Fast Track ,Chinese Academy ,Emergency Use Authorizations ,Shanghai Junshi Biosciences Co ,Td Stock Exchange ,News ,Information ,Press Release ,Junshi ,Iosciences ,End ,Coherus ,Plan ,O ,Valuate ,The ,Toripalimab ,S006 ,Combination ,N ,Linical ,Trials ,Multiple ,Humor ,Ypescombinations ,F ,Digit ,Inhibitors ,Wave ,Potential ,O 1877 Cne100003ff7 ,